Table 1.
Clinical Characteristics of the Cohort
| n | ||
|---|---|---|
| Age at diagnosis, y | 43 | |
| Mean ± SD | 54 ± 20 | |
| Median | 58 | |
| Range | 13–85 | |
| Gender | ||
| Male | 60% | 26 |
| Histology | ||
| Poorly differentiated | 33% | 14 |
| Classical papillary | 28% | 12 |
| Follicular variant papillary | 19% | 8 |
| Tall cell variant papillary | 9% | 4 |
| Other papillary | 5% | 2 |
| Follicular | 5% | 2 |
| Hurthle cell | 2% | 1 |
| Structurally evident metastases at ablation | ||
| None | 7 | |
| Lungs | 57% | 20 |
| Mixed | 37% | 13 |
| Bone | 6% | 2 |
| Size of lung metastasis | 32 | |
| <1 cm | 72% | 23 |
| ≥ 1 cm | 28% | 9 |
| AJCC stage | ||
| II | 42% | 18 |
| IV | 58% | 25 |
| FDG-PET imaging | 29 | |
| Abnormal | 55% | 16 |
| Normal | 45% | 13 |
| Preparation for ablation | ||
| rhTSH | 67% | 29 |
| Thyroid hormone withdrawal | 33% | 14 |
| Suppressed Tg before ablation (ng/mL)a | 34 | |
| Mean ± SD | 2536.4 ± 9602.7.5 | |
| Median | 9.6 | |
| Range | <0.2–54 000 | |
| DxWBS before ablation | ||
| Positive | 44% | 19 |
| 131I Ablation administered activity (mCi) | ||
| Mean ± SD | 195.2 ± 77 | |
| Median | 155 | |
| Range | 76–501 | |
| RAI therapies including ablation, n | ||
| Mean ± SD | 2.2 ± 1.2 | |
| Median | 2 | |
| Range | 1–5 | |
| 131I Cumulative administered activity (mCi) | ||
| Mean ± SD | 558.4 ± 439 | |
| Median | 501 | |
| Range | 76–1805 | |
| Follow-up duration, y | ||
| Mean ± SD | 5.0 ± 4.2 | |
| Median | 3.6 | |
| Range | 1- 17 |
Abbreviation: rhTSH, recombinant human TSH; AJCC, American Joint Committee on Cancer.
a
Two patients had positive TgAb at RAI ablation and reverted to detectable TgAb by the end of the study.